Mode
Text Size
Log in / Sign up
N/A N=23 Randomized Triple-blind Treatment

Treating Phobia With Multivoxel Neuro-reinforcement

Phobia

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Change in Amygdala Reactivity — -.691; -.827; -.278 Beta Coefficient

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Unconscious Neuro-reinforcement (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of California, Los Angeles
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Amygdala Reactivity
-.691; -.827; -.278
PRIMARY
Subjective Fear Post-treatment Minus Pre-treatment
0.32; -0.03; 0.43
SECONDARY
Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment
-0.010; -0.097; -0.030
SECONDARY
Fear Survey Schedule
-2.46; -5.00; -11.93
SECONDARY
Stroop Task Post-treatment Minus Pre-treatment
-0.080; -0.137; -0.030

Summary

Specific phobias and other anxiety disorders represent a major mental health problem, and present a significant challenge to researchers because effective treatment usually involves repeated exposure to feared stimuli, and the high levels of associated distress can lead to termination of treatment. Recent advances in computational functional magnetic resonance imaging (fMRI) provide a method by which individuals may be unconsciously exposed to fearful stimuli, leading to effective fear reduction while eliminating a primary cause of attrition. The objective of the current study is to use the novel approach of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli (e.g., spiders, heights) in individuals with phobias, directly and unconsciously in the brain, without repeatedly exposing participants to their feared stimuli. Participants will be randomized into one of three groups of varying neuro-reinforcement sessions (1, 3, or 5). They will complete tests of subjective fear and directed attention while being scanned by fMRI to measure engagement of amygdala activity to fearful stimuli as well as measured through other indicators of fear such as skin conductance response.

Eligibility Criteria

Inclusion Criteria

  • Individual has normal or corrected to normal vision
  • Individual has normal or corrected to normal hearing
  • Individual is competent to understand informed consent

Exclusion Criteria

  • Individual is unable to fill in consent form correctly
  • Individual is unable to respond adequately to screening questions
  • Individual is unable to maintain focus or to sit during assessment
  • Individual has history of: neurological disease or defect (e.g., stroke, traumatic brain injury, schizophrenia or other psychological disorders, or seizures)
  • Individual has vision problems (including cataracts, amblyopia, or glaucoma)
  • Individual presents with: PTSD, Obsessive Compulsive Disorder, Substance Use Disorder, Current Major Depression, Bipolar Disorder, Psychosis, neurologic diagnoses or unstable serious medical conditions
  • Individual does not present with more than one object of specific phobia
  • Individual can touch the phobic object category during the pre¬treatment Behavioral Approach Test without presenting significant distress
  • Individual is currently prescribed psychotropic medication
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03655262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search